287 results on '"Gruben, David"'
Search Results
2. Experience with Tofacitinib in Patients with Ulcerative Colitis: Data from a United States Claims Database
3. High Usability and Applicability Ratings for the New SmartClic®/ClicWise® Injection Device: Evidence from a Health Care Professional Opinion Study
4. Early Real-World Experience of Tofacitinib for Psoriatic Arthritis: Data from a United States Healthcare Claims Database
5. Economic Burden and Healthcare Resource Use of Alopecia Areata in an Insured Population in the USA
6. Clinical and Humanistic Burden of Atopic Dermatitis in Europe: Analyses of the National Health and Wellness Survey
7. Predictors of nonresponse to dupilumab in patients with atopic dermatitis: A machine learning analysis
8. Impact of Methotrexate Discontinuation, Interruption, or Persistence in US Patients with Rheumatoid Arthritis Initiating Tofacitinib + Oral Methotrexate Combination
9. The impact of tofacitinib on fatigue, sleep, and health-related quality of life in patients with rheumatoid arthritis: a post hoc analysis of data from Phase 3 trials
10. Clinical and Economic Burden of Mild-to-Moderate Atopic Dermatitis in the UK: A Propensity-Score-Matched Case–Control Study
11. Psychosocial Comorbidities and Health Status Among Adults with Moderate-to-Severe Atopic Dermatitis: A 2017 US National Health and Wellness Survey Analysis
12. The Economic and Psychosocial Comorbidity Burden Among Adults with Moderate-to-Severe Atopic Dermatitis in Europe: Analysis of a Cross-Sectional Survey
13. Real-World Evidence to Contextualize Clinical Trial Results and Inform Regulatory Decisions: Tofacitinib Modified-Release Once-Daily vs Immediate-Release Twice-Daily for Rheumatoid Arthritis
14. Tofacitinib Efficacy in Patients with Rheumatoid Arthritis and Probable Depression/Anxiety: Post Hoc Analysis of Phase 3 and 3b/4 Randomized Controlled Trials
15. Identification of Distinct Disease Activity Trajectories in Methotrexate‐Naive Patients With Rheumatoid Arthritis Receiving Tofacitinib Over Twenty‐Four Months
16. Real-World Comparative Effectiveness of Tofacitinib and Tumor Necrosis Factor Inhibitors as Monotherapy and Combination Therapy for Treatment of Rheumatoid Arthritis
17. Real-world Effectiveness of Advanced Therapies Among Patients With Moderate to Severe Ulcerative Colitis in the United States
18. Sex differences in the efficacy, safety and persistence of patients with psoriatic arthritis treated with tofacitinib: a post-hoc analysis of phase 3 trials and long-term extension
19. Initial Experience With Tofacitinib in Clinical Practice: Treatment Patterns and Costs of Tofacitinib Administered as Monotherapy or in Combination With Conventional Synthetic DMARDs in 2 US Health Care Claims Databases
20. Plain language summary for the manuscript: Sex differences in the efficacy, safety, and persistence of patients with psoriatic arthritis treated with tofacitinib: a post-hoc analysis of phase 3 trials and long-term extension
21. Predictive Modeling in HEOR
22. Comorbidities, Healthcare Utilization, and Costs Associated With Alopecia Totalis and Alopecia Universalis in the United States
23. 34653 Atopic dermatitis treatment patterns and patient burden in Russia and Poland
24. High Usability and Applicability Ratings for the New SmartClic®/ClicWise® Injection Device: Evidence from a Health Care Professional Opinion Study.
25. Tu1823 BAYESIAN NETWORK META-ANALYSIS OF THE EFFICACY OF ADVANCED THERAPIES FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS NAÏVE TO ADVANCED THERAPY
26. Additional file 1 of The impact of tofacitinib on fatigue, sleep, and health-related quality of life in patients with rheumatoid arthritis: a post hoc analysis of data from Phase 3 trials
27. Effectiveness and Safety of Tofacitinib in Canadian Patients With Rheumatoid Arthritis: Primary Results From a Prospective Observational Study.
28. Identification of Distinct Disease Activity Trajectories in Methotrexate‐Naive Patients With Rheumatoid Arthritis Receiving Tofacitinib Over Twenty‐Four Months
29. Retrospective Database Analysis: Dose Escalation and Adherence in Patients Initiating Biologics for Ulcerative Colitis
30. Supplement to: Tofacitinib versus methotrexate in rheumatoid arthritis.
31. Demographic diversity of participants in Pfizer sponsored clinical trials in the United States
32. High Usability and Applicability Ratings for the New SmartClic®/ClicWise®Injection Device: Evidence from a Health Care Professional Opinion Study
33. Retrospective Database Analysis: Dose Escalation and Adherence in Patients Initiating Biologics for Ulcerative Colitis.
34. Fr122 CLINICAL CHARACTERISTICS AND HEALTHCARE RESOURCE UTILIZATION IN A REAL-WORLD COHORT OF PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB
35. Tofacitinib versus Methotrexate in Rheumatoid Arthritis
36. 16443 Prevalence and impact of psychosocial comorbidities on health status among patients with moderate to severe atopic dermatitis in the United States: Analysis of the 2017 US National Health and Wellness Survey
37. 16434 Health status, work productivity, and health care resource utilization in patients with moderate to severe atopic dermatitis: Analysis of the 2017 United States National Health and Wellness Survey
38. 16889 The economic burden of mild to moderate atopic dermatitis in the United States: Analyses of the National Health and Wellness Survey
39. 16882 The clinical and humanistic burden of mild to moderate atopic dermatitis in the United States: Analyses of the National Health and Wellness Survey
40. The Economic and Psychosocial Comorbidity Burden Among Adults with Moderate-to-Severe Atopic Dermatitis in Europe: Analysis of a Cross-Sectional Survey
41. Real-World Evidence to Contextualize Clinical Trial Results and Inform Regulatory Decisions: Tofacitinib Modified-Release Once-Daily vs Immediate-Release Twice-Daily for Rheumatoid Arthritis
42. Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: A Randomized Trial
43. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four–month phase III randomized radiographic study
44. Tofacitinib and Adalimumab Achieve Similar Rates of Low Disease Activity in Rheumatoid Arthritis—Lack of Improvement in Disease Activity Score by 3 Months Predicts Low Likelihood of Low Disease Activity At 1 Year.: 1297
45. Serious adverse events—Missing in action: Comment on the article by Kremer et al
46. Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
47. Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
48. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone
49. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs
50. Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.